Behavioral Interventions for Diabetes
(STIC2IT-2 Trial)
Trial Summary
What is the purpose of this trial?
The overarching goal of the proposed research is to prepare the clinical pharmacist intervention for sustainable implementation and dissemination. Because the effectiveness of the intervention has already been demonstrated in a NIH Stage Model IV trial, the investigators propose an Effectiveness-Implementation Type 3 Hybrid design, in which the primary focus is on testing different implementation methods, while secondarily observing clinical effects. The investigators' overarching hypothesis is to identify the most impactful elements of a behavioral theory-informed recruitment approach, which can be replicable across clinical settings. Accordingly, the investigators propose to perform testing of a behaviorally-informed recruitment approaches in a community-based setting. Like the previous Tele-Pharmacy Intervention to Improve Treatment Adherence (STIC2IT) trial (NCT02512276), participants will be English or Spanish speaking adults ≥18 years of age identified through the electronic health record (EHR) as having poor disease control and/or poor medication adherence for diabetes. The primary care physicians of eligible patients identified through the EHR will be contacted to opt-out any patients they wish not to be included. Patients will then be randomized to each of the following conditions, such that there will be 8 total arms: (1) inclusion of a mailer primer (yes/no), (2) the most successful recruitment letter from the preliminary study using prospect theory (versus the control letter), and (3) intensity of the intervention outreach (4 calls vs. 2 calls). The investigators plan to enroll 584 participants who meet the inclusion criteria, with 73 patients per each of the 8 study arms. Patients across all arms who agree to be scheduled will receive an appointment with one of the clinical pharmacists within the established BMC pharmacist program. The primary outcome will be completion of a clinical pharmacist appointment within 8 weeks after randomization. Key secondary outcomes will include scheduled visit rates, no-show rates for scheduled appointments, medication adherence over the 3-month follow-up, and clinical outcomes, including HbA1c levels measured using EHR data in the 3 months after randomization. The medication adherence and clinical outcomes will be used for the Aim 2 evaluation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It focuses on improving medication adherence, so it's likely you will continue your current diabetes medications.
What data supports the effectiveness of the treatment Behavioral Medication Adherence Interventions for diabetes?
Research shows that improving medication adherence through behavioral interventions can lead to better health outcomes for people with diabetes. These interventions often include strategies like positive reinforcement and simplifying treatment plans, which help patients stick to their medication schedules and improve their quality of life.12345
Is it safe to participate in behavioral interventions for diabetes?
Behavioral interventions for diabetes, which focus on improving lifestyle habits and medication adherence, are generally considered safe for humans. These interventions have been used to support better health outcomes in people with diabetes, and no significant safety concerns have been reported in the research.678910
How is the Behavioral Medication Adherence Interventions treatment for diabetes unique?
This treatment is unique because it focuses on changing patient behavior to improve medication adherence, rather than just increasing knowledge about diabetes. It emphasizes communication between patients and healthcare providers and considers individual and community factors to optimize behavior change.4671112
Research Team
Niteesh K Choudhry, MD, PhD
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for English or Spanish speaking adults over 18 who have diabetes, are treated by a BMC primary care provider, and struggle with taking their medication as prescribed. They should also show signs of poor diabetes control. Patients will be excluded if their doctor thinks they shouldn't participate.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Randomization and Intervention
Participants are randomized into 8 arms to test different recruitment methods and intervention outreach intensities
Follow-up
Participants are monitored for medication adherence and clinical outcomes, including HbA1c levels
Treatment Details
Interventions
- Behavioral Medication Adherence Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
National Institute on Aging (NIA)
Collaborator
Boston Medical Center
Collaborator
Columbia University
Collaborator